I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH ...

Shares of Equifax Inc. EFX slid 2.06% to $248.07 Thursday, on what proved to be an all-around mixed trading session for the ...

A number of stocks jumped in the afternoon session after markets continued to rally as investor optimism grew for a potential ...

Recent data from the New York Federal Reserve Bank and Equifax (NYSE:EFX) highlight a troubling trend in U.S. consumer ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

We are not close. After my father passed, she kicked us to the curb - not only financially but also emotionally and as a parent. Even though I was 20 when he died, I grew up in a family where we were ...

Quality boots, weather systems, and field accessories were among the highlights of this year's product launches. Here’s what ...

Reports of inadequate liquidity have been greatly exaggerated, but the high-volatility environment in the first six months of ...